CLINICAL TRIALS PROFILE FOR INSULIN DEGLUDEC; LIRAGLUTIDE
✉ Email this page to a colleague
All Clinical Trials for Insulin Degludec; Liraglutide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01319240 ↗ | Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects | Completed | Novo Nordisk A/S | Phase 1 | 2011-03-01 | This trial is conducted in Europe. The aim of this trial is to compare the bioavailability of insulin degludec and liraglutide, when administered either combined or as separate administrations. |
| NCT01336023 ↗ | Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes | Completed | Novo Nordisk A/S | Phase 3 | 2011-05-23 | This trial is conducted globally. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (IDeg) and liraglutide (Lira) in subjects with type 2 diabetes. Subjects are to continue their pre-trial treatment with metformin or metformin + pioglitazone throughout the entire trial. |
| NCT01388361 ↗ | Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin | Completed | Novo Nordisk A/S | Phase 3 | 2011-09-01 | This trial is conducted in Europe and North America. The aim of this trial is to compare the efficacy and safety of adding liraglutide versus addition of insulin aspart with the largest meal to insulin degludec in subjects with type 2 diabetes. Eligible subjects with an HbA1c equal to or above 7% at end of treatment in NN1250-3643 (NCT01193309) trial will be randomised to receive treatment intensification while subjects with an HbA1c below 7% at end of treatment in NN1250-3643 (NCT01193309) may continue to receive insulin degludec treatment. Subjects are to continue their pre-trial metformin treatment. |
| NCT01392573 ↗ | A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes | Completed | Novo Nordisk A/S | Phase 3 | 2011-11-28 | This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) and insulin degludec (IDeg) in subjects with type 2 diabetes. Subjects continue their pre-trial treatment with metformin throughout the entire trial. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Insulin Degludec; Liraglutide
Condition Name
Clinical Trial Locations for Insulin Degludec; Liraglutide
Trials by Country
Clinical Trial Progress for Insulin Degludec; Liraglutide
Clinical Trial Phase
Clinical Trial Sponsors for Insulin Degludec; Liraglutide
Sponsor Name
